MAPT and Alzheimer disease: In AD, axonopathy and white matter alterations are observed from the early stage prior to the onset of severe cognitive symptoms9–11, while in the later disease stage, increase of cerebrospinal fluid (CSF) neurofilament light, a biomarker for axonal damage, is correlated with cognitive dysfunction and tau pathology12–14.